Literature DB >> 26154438

Effects of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine on visual signal detection performance in rats.

Todd M Hillhouse1, Christina R Merritt, Joseph H Porter.   

Abstract

The noncompetitive N-methyl-D-aspartate receptor antagonist ketamine produces consistent, rapid, and sustained antidepressant effects in patients suffering from treatment-resistant depression. However, ketamine-induced cognitive impairments remain a major concern. The present study sought to extend the preclinical evaluation of ketamine-induced cognitive impairments by evaluating the dose (1.0-18.0 mg/kg) and time-course (10 min-24 h) of effects of ketamine on sustained attention using a visual signal detection procedure in rats. Overall, ketamine (10.0-18.0 mg/kg) dose-dependently decreased percent hit and correct rejection accuracy. Additionally, these same doses of ketamine increased response latency and trial omissions. In the time-course study, treatment with 18.0 mg/kg ketamine produced the greatest decrease in visual signal detection performance at 10 min, when ketamine decreased percent hit and correct rejection accuracy as well as increased response latency and trial omissions, but returned to saline baseline controls by 100 min. In conclusion, acute ketamine inhibited sustained attention in rats performing a visual signal detection task; however, these effects were short in duration, similar to the short duration (<2 h) of psychotomimetic effects reported in low-dose ketamine treatment in depressed patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26154438      PMCID: PMC4499864          DOI: 10.1097/FBP.0000000000000160

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  26 in total

Review 1.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

2.  Effects of the neurotensin NTS₁ receptor agonist PD149163 on visual signal detection in rats.

Authors:  Todd M Hillhouse; Adam J Prus
Journal:  Eur J Pharmacol       Date:  2013-09-25       Impact factor: 4.432

3.  Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics.

Authors:  Tomáš Páleníček; Michaela Fujáková; Martin Brunovský; Marie Balíková; Jiří Horáček; Ingmar Gorman; Filip Tylš; Barbora Tišlerová; Peter Soš; Věra Bubeníková-Valešová; Cyril Höschl; Vladimír Krajča
Journal:  Neuropsychobiology       Date:  2011-03-22       Impact factor: 2.328

4.  Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats.

Authors:  Amir H Rezvani; Ehsan Kholdebarin; Elizabeth Dawson; Edward D Levin
Journal:  Int J Neuropsychopharmacol       Date:  2007-02-13       Impact factor: 5.176

5.  Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain.

Authors:  Gislaine Z Réus; Roberto B Stringari; Karine F Ribeiro; Ana K Ferraro; Marcelo F Vitto; Patrícia Cesconetto; Claúdio T Souza; João Quevedo
Journal:  Behav Brain Res       Date:  2011-03-21       Impact factor: 3.332

6.  Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study.

Authors:  Celia J A Morgan; Ali Mofeez; Brigita Brandner; Lesley Bromley; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

7.  Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia.

Authors:  Gary Gilmour; Elsa Y Pioli; Sophie L Dix; Janice W Smith; Michael W Conway; Wendy T Jones; Sally Loomis; Rebecca Mason; Shahram Shahabi; Mark D Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2009-05-07       Impact factor: 4.530

8.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

9.  Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

10.  Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation.

Authors:  Celia J A Morgan; Chris M Dodds; Hannah Furby; Fiona Pepper; Johnson Fam; Tom P Freeman; Emer Hughes; Christian Doeller; John King; Oliver Howes; James M Stone
Journal:  Front Psychiatry       Date:  2014-12-04       Impact factor: 4.157

View more
  2 in total

1.  Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats.

Authors:  Alan L Pehrson; Todd M Hillhouse; Nasser Haddjeri; Renaud Rovera; Joseph H Porter; Arne Mørk; Gennady Smagin; Dekun Song; David Budac; Manuel Cajina; Connie Sanchez
Journal:  J Pharmacol Exp Ther       Date:  2016-07-11       Impact factor: 4.030

2.  Vortioxetine Differentially Modulates MK-801-Induced Changes in Visual Signal Detection Task Performance and Locomotor Activity.

Authors:  Todd M Hillhouse; Christina R Merritt; Douglas A Smith; Manuel Cajina; Connie Sanchez; Joseph H Porter; Alan L Pehrson
Journal:  Front Pharmacol       Date:  2018-09-13       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.